Neuropsychological effects of tiagabine, a potential new antiepileptic drug

S. Sveinbjornsdottir, J. W.A.S. Sander, P. N. Patsalos, D. Upton, P. J. Thompson, J. S. Duncan

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

The neuropsychological effects of the GABA-reuptake blocker, tiagabine-HCl, were tested in an open trial of 22 adult patients with refractory partial epilepsy followed by a double-blind, placebo-controlled, cross-over trial in 12 subjects. Nineteen patients completed the initial open titration and fixed-dose phase of the study and 11 patients completed the double-blind phase. The median daily tiagabine dose was 32 mg during the open fixed dose and 24 mg during the double-blind periods. Neuropsychological evaluation did not show any significant effect on cognitive function in the open or double-blind phases. In this group of patients no statistically significant difference in the frequency of the total number of seizures or complex partial seizures was found in the open or double-blind stages. Seizure severity was significantly less in the open fixed dose than in the baseline period, but was not significantly different between the two double-blind periods. Reported side effects were transient, most commonly aggression/irritability, lethargy, headache and drowsiness. No significant EEG changes were observed.

Original languageEnglish
Pages (from-to)29-35
Number of pages7
JournalSeizure
Volume3
Issue number1
DOIs
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Anticonvulsants
Seizures
Lethargy
Partial Epilepsy
Sleep Stages
Aggression
Cross-Over Studies
gamma-Aminobutyric Acid
Cognition
Headache
Electroencephalography
Placebos
tiagabine

Cite this

Sveinbjornsdottir, S., Sander, J. W. A. S., Patsalos, P. N., Upton, D., Thompson, P. J., & Duncan, J. S. (1994). Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure, 3(1), 29-35. https://doi.org/10.1016/S1059-1311(05)80160-8
Sveinbjornsdottir, S. ; Sander, J. W.A.S. ; Patsalos, P. N. ; Upton, D. ; Thompson, P. J. ; Duncan, J. S. / Neuropsychological effects of tiagabine, a potential new antiepileptic drug. In: Seizure. 1994 ; Vol. 3, No. 1. pp. 29-35.
@article{034d5e4e8d9b4371a3c81ec1096031a7,
title = "Neuropsychological effects of tiagabine, a potential new antiepileptic drug",
abstract = "The neuropsychological effects of the GABA-reuptake blocker, tiagabine-HCl, were tested in an open trial of 22 adult patients with refractory partial epilepsy followed by a double-blind, placebo-controlled, cross-over trial in 12 subjects. Nineteen patients completed the initial open titration and fixed-dose phase of the study and 11 patients completed the double-blind phase. The median daily tiagabine dose was 32 mg during the open fixed dose and 24 mg during the double-blind periods. Neuropsychological evaluation did not show any significant effect on cognitive function in the open or double-blind phases. In this group of patients no statistically significant difference in the frequency of the total number of seizures or complex partial seizures was found in the open or double-blind stages. Seizure severity was significantly less in the open fixed dose than in the baseline period, but was not significantly different between the two double-blind periods. Reported side effects were transient, most commonly aggression/irritability, lethargy, headache and drowsiness. No significant EEG changes were observed.",
keywords = "neuropsychology, partial seizures, tiagabine",
author = "S. Sveinbjornsdottir and Sander, {J. W.A.S.} and Patsalos, {P. N.} and D. Upton and Thompson, {P. J.} and Duncan, {J. S.}",
year = "1994",
doi = "10.1016/S1059-1311(05)80160-8",
language = "English",
volume = "3",
pages = "29--35",
journal = "Seizure : the journal of the British Epilepsy Association",
issn = "1059-1311",
publisher = "W.B. Saunders Ltd",
number = "1",

}

Sveinbjornsdottir, S, Sander, JWAS, Patsalos, PN, Upton, D, Thompson, PJ & Duncan, JS 1994, 'Neuropsychological effects of tiagabine, a potential new antiepileptic drug', Seizure, vol. 3, no. 1, pp. 29-35. https://doi.org/10.1016/S1059-1311(05)80160-8

Neuropsychological effects of tiagabine, a potential new antiepileptic drug. / Sveinbjornsdottir, S.; Sander, J. W.A.S.; Patsalos, P. N.; Upton, D.; Thompson, P. J.; Duncan, J. S.

In: Seizure, Vol. 3, No. 1, 1994, p. 29-35.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Neuropsychological effects of tiagabine, a potential new antiepileptic drug

AU - Sveinbjornsdottir, S.

AU - Sander, J. W.A.S.

AU - Patsalos, P. N.

AU - Upton, D.

AU - Thompson, P. J.

AU - Duncan, J. S.

PY - 1994

Y1 - 1994

N2 - The neuropsychological effects of the GABA-reuptake blocker, tiagabine-HCl, were tested in an open trial of 22 adult patients with refractory partial epilepsy followed by a double-blind, placebo-controlled, cross-over trial in 12 subjects. Nineteen patients completed the initial open titration and fixed-dose phase of the study and 11 patients completed the double-blind phase. The median daily tiagabine dose was 32 mg during the open fixed dose and 24 mg during the double-blind periods. Neuropsychological evaluation did not show any significant effect on cognitive function in the open or double-blind phases. In this group of patients no statistically significant difference in the frequency of the total number of seizures or complex partial seizures was found in the open or double-blind stages. Seizure severity was significantly less in the open fixed dose than in the baseline period, but was not significantly different between the two double-blind periods. Reported side effects were transient, most commonly aggression/irritability, lethargy, headache and drowsiness. No significant EEG changes were observed.

AB - The neuropsychological effects of the GABA-reuptake blocker, tiagabine-HCl, were tested in an open trial of 22 adult patients with refractory partial epilepsy followed by a double-blind, placebo-controlled, cross-over trial in 12 subjects. Nineteen patients completed the initial open titration and fixed-dose phase of the study and 11 patients completed the double-blind phase. The median daily tiagabine dose was 32 mg during the open fixed dose and 24 mg during the double-blind periods. Neuropsychological evaluation did not show any significant effect on cognitive function in the open or double-blind phases. In this group of patients no statistically significant difference in the frequency of the total number of seizures or complex partial seizures was found in the open or double-blind stages. Seizure severity was significantly less in the open fixed dose than in the baseline period, but was not significantly different between the two double-blind periods. Reported side effects were transient, most commonly aggression/irritability, lethargy, headache and drowsiness. No significant EEG changes were observed.

KW - neuropsychology

KW - partial seizures

KW - tiagabine

UR - http://www.scopus.com/inward/record.url?scp=0028303908&partnerID=8YFLogxK

U2 - 10.1016/S1059-1311(05)80160-8

DO - 10.1016/S1059-1311(05)80160-8

M3 - Article

VL - 3

SP - 29

EP - 35

JO - Seizure : the journal of the British Epilepsy Association

JF - Seizure : the journal of the British Epilepsy Association

SN - 1059-1311

IS - 1

ER -

Sveinbjornsdottir S, Sander JWAS, Patsalos PN, Upton D, Thompson PJ, Duncan JS. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure. 1994;3(1):29-35. https://doi.org/10.1016/S1059-1311(05)80160-8